The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Advances and perspectives of PARP inhibitors
Open accessAbstract
DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive genome instability and catastrophic DNA damage. Continuous DNA replication in cancer cells leads to higher demand of DNA repair components. Due to the oncogenic loss of some DNA repair effectors (e.g. BRCA) and incomplete DNA repair repertoire, some cancer cells are addicted to certain DNA repair pathways such as Poly (ADP-ribose) polymerase (PARP)-related single-strand break repair pathway. The interaction between BRCA and PARP is a form of synthetic lethal effect which means the simultaneously functional loss of two genes lead to cell death, while defect in any single gene has a slight effect on cell viability. Based on synthetic lethal theory, Poly (ADP-ribose) polymerase inhibitor (PARPi) was developed aiming to selectively target cancer cells harboring BRCA1/2 mutations. Recently, a growing body of evidence indicated that a broader population of patients could benefit from PARPi therapy far beyond those with germline BRCA1/2 mutated tumors. Numerous biomarkers including homologous recombination deficiency and high level of replication pressure also herald high sensitivity to PARPi treatment. Besides, a series of studies indicated that PARPi-involved combination therapy such as PARPi with additional chemotherapy therapy, immune checkpoint inhibitor, as well as targeted agent had a great advantage in overcoming PARPi resistance and enhancing PARPi efficacy. In this review, we summarized the advances of PARPi in clinical application. Besides, we highlighted multiple promising PARPi-based combination strategies in preclinical and clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 PARP and PARPis. a The structure schematic of PARP molecule. There are six main domains of PARP1 which include three zinc finger-related domains (DNA binding domains), one BRCA1 C-terminus domain (auto-modification domain), one tryptophan-/glycine-/arginine-rich domain (WGR domain), and one catalytic domain. The catalytic domain of PARP1 consists of two subdomains: one helical domain (HD) and one ADP-ribosyltransferase catalytic domain (ART). b Three-dimensional structure of PARP1 molecule. The above structures were presented by PyMOL Molecular Graphics System (PDB ID: 5XST [104]). c The chemistry structural formula of PARPis. d The function of PARP and synthetic lethal interaction between PARP and HR. Once DNA SSB emerges, PARP1 could recognizes and interacts with SSB by its zinc finger-related domains. After PARP1 binding to damaged DNA chains, the auto-inhibitory function of HD is abrogated and the catalytic function of ART is activated. This catalytic activity leads to the generation of PAR chains on a series of target proteins which promotes the recruitment of DNA repair effectors and chromatin remodeling. Then the auto-PARylation on PARP1 protein causes the dissociation of PARP1 from DNA chains and restores the auto-inhibitory status of PARP1. For HR deficient tumor cells, active SSB repair pathways is the vital prerequisites for cell survival. After PARPi treatment, NHEJ is used to repair PARPi-introduced DSB. However, NHEJ is a rapid as well as error-prone repair pathway by direct ligation. Due to the low-fidelity, NHEJ often produces plenty of chromosomal rearrangements and these unsustainable DNA damages are harmful to cell viability](/paper-figures/b8cba8b0fd6c416cb14979296998b864/advances-and-perspectives-of-parp-inhibitors-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As the core of SSB repair, PARP is the ideal target for drug development [222].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [222]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,452
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X. L., Fernandez‐Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,362
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Self-citationCD44 as a tumor biomarker and therapeutic target
Xu, H., Niu, M., Yuan, X., Wu, K., & Liu, A. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00192-0 · Cited by 390
Self-citationRecent advances in targeted strategies for triple-negative breast cancer
Zhu, S., Wu, Y., Song, B., Yi, M., Yan, Y., Mei, Q., & Wu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01497-3 · Cited by 351
Self-citationThe therapeutic potential of targeting regulated non-apoptotic cell death
Hadian, K., & Stockwell, B. R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00749-8 · Cited by 349
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 343
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 315
Wang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 157
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Min, A., & Im, S. (2020) · Cancers · doi:10.3390/cancers12020394 · Cited by 134
Inhibitors of PARP: Number crunching and structure gazing
Rudolph, J., Jung, K., & Luger, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121979119 · Cited by 121
PARP1: Structural insights and pharmacological targets for inhibition
Spiegel, J. O., Houten, B. V., & Durrant, J. D. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103125 · Cited by 108
Subhan, M. A., Parveen, F., Shah, H., Yalamarty, S. S. K., Ataide, J. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15082204 · Cited by 108
Borella, F., Ghisoni, E., Giannone, G., Cosma, S. D., Benedetto, C., Valabrega, G., & Katsaros, D. (2020) · Diagnostics · doi:10.3390/diagnostics10030146 · Cited by 95
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Patel, P. S., Algouneh, A., & Hakem, R. (2021) · Oncogene · doi:10.1038/s41388-021-01744-2 · Cited by 98
Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Gallyas, F., Sümegi, B., & Szabó, C. (2020) · Cancers · doi:10.3390/cancers12030532 · Cited by 79
Patel, M. A., Nowsheen, S., Maraboyina, S., & Xia, F. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00390-7 · Cited by 78
Zhang, X., Wang, Y., A, G., Qu, C., & Chen, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.721030 · Cited by 76
HPF1 and nucleosomes mediate a dramatic switch in activity of PARP1 from polymerase to hydrolase
Rudolph, J., Roberts, G., Muthurajan, U. M., & Luger, K. (2021) · eLife · doi:10.7554/elife.65773 · Cited by 75
Gao, Y., Zhang, H., Lirussi, F., Garrido, C., Ye, X., & Xie, T. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114224 · Cited by 73
The role of SOX family transcription factors in gastric cancer
Abadi, A. J., Zarrabi, A., Hashemi, F., Zabolian, A., Najafi, M., Entezari, M., Hushmandi, K., Aref, A. R., Khan, H. Z., Makvandi, P., et al. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.202 · Cited by 70
Understanding genomics and the immune environment of penile cancer to improve therapy
Aydın, A. M., Chahoud, J., Adashek, J. J., Azizi, M., Magliocco, A. M., Ross, J. S., Necchi, A., & Spiess, P. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0359-z · Cited by 66
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Rudolph, J., Roberts, G., & Luger, K. (2021) · Nature Communications · doi:10.1038/s41467-021-20998-8 · Cited by 61
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 52
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
Seeber, A., Zimmer, K., Kocher, F., Puccini, A., Xiu, J., Nabhan, C., Elliott, A., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000942 · Cited by 52
Heterocycles in drug discovery: Properties and preparation
Rotella, D. P. (2020) · Advances in heterocyclic chemistry · doi:10.1016/bs.aihch.2020.10.002 · Cited by 48
Nickoloff, J. A., Taylor, L., Sharma, N., & Kato, T. A. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.89 · Cited by 47
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
Congregado, B., BELENCHON, I. R., Osman, I., Sáez, C., & López, R. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10061416 · Cited by 48
Hodgson, D., Lai, Z., Dearden, S. P., Barrett, J. C., Harrington, E. A., Timms, K. M., Lanchbury, J. S. S., Wu, W., Allen, A., Senkus, E., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2154 · Cited by 44
Woll, P. J., Gaunt, P., Danson, S. J., Steele, N. L., Ahmed, S. I., Mulatero, C., Shah, R. N. H., Bhosle, J., Hodgkinson, E., Watkins, B., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.07.007 · Cited by 43
The treatment landscape of triple-negative breast cancer
Hu, Y., Wang, C., Liang, H., Li, J., & Yang, Q. (2024) · Medical Oncology · doi:10.1007/s12032-024-02456-9 · Cited by 42
Böhi, F., Manetsch, P., & Hottiger, M. O. (2021) · Cell Discovery · doi:10.1038/s41421-021-00323-9 · Cited by 46
Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
Drakes, M. L., Czerlanis, C. M., & Stiff, P. J. (2020) · Cancers · doi:10.3390/cancers12113301 · Cited by 34
Yu, P., Wang, Y., Yuan, D., Sun, Y., Qin, S., & Li, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1276694 · Cited by 36
Self-citationConceição, C. J. F., Moe, E., Ribeiro, P. A., & Raposo, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189282 · Cited by 32
RDGN-based predictive model for the prognosis of breast cancer
Dong, B., Yi, M., Luo, S., Li, A., & Wu, K. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00169-z · Cited by 29
Self-citationComprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00952-9 · Cited by 30
Tiwari, P., Khan, H., Singh, T. G., & Grewal, A. K. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03595-z · Cited by 28
Kim, Y., Kim, S.-B., Choi, S.-H., Nguyen, T., Ahn, S., Moon, K., Cho, K.-H., Sim, T., Heo, E.-J., Kim, S. T., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061669 · Cited by 27
Zhou, J., Ji, M., Wang, X., Zhao, H., Cao, R., Jin, J., Li, Y., Chen, X., Li, S., Chen, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01522 · Cited by 27
Mahadevan, J., Jha, A., Rudolph, J., Bowerman, S., Narducci, D. N., Hansen, A. S., & Luger, K. (2022) · iScience · doi:10.1016/j.isci.2022.105779 · Cited by 26
Arena, A., Montani, M. S. G., Romeo, M. A., Benedetti, R., Gaeta, A., & Cirone, M. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119168 · Cited by 25
Wang, Y., Li, K., Xu, W., & Gou, S.-H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106759 · Cited by 23
Zhou, J., Du, T., Wang, X., Yao, H., Deng, J., Li, Y., Chen, X., Li, S., Ji, M., & Xu, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01152 · Cited by 24
Bakr, A., Hey, J., Sigismondo, G., Liu, C.-S., Sadik, A., Goyal, A., Cross, A., Iyer, R. L., Müller, P., Trauernicht, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab964 · Cited by 24
Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic
Zhang, Y., Wu, L., Wang, Z., Wang, J., Roychoudhury, S., Tomasik, B., Wu, G., Wang, G., Rao, X., & Zhou, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.838637 · Cited by 24
Juan, A., Noblejas‐López, M. D. M., Bravo, I., Arenas-Moreira, M., Blasco-Navarro, C., Clemente-Casares, P., Lara‐Sánchez, A., Pandiella, A., Alonso‐Moreno, C., & Ocaña, A. (2022) · Cancers · doi:10.3390/cancers14184474 · Cited by 18
Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape
Salguero‐Aranda, C., Amaral, A. T., Olmedo-Pelayo, J., Díaz‐Martín, J., & de Álava, E. (2020) · Cells · doi:10.3390/cells9040804 · Cited by 19
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Liontos, M., Terpos, E., Markellos, C., Zagouri, F., Briasoulis, Α., Katsiana, I., Skafida, E., Fiste, O., Kunadis, E., Andrikopoulou, Α., et al. (2021) · Vaccines · doi:10.3390/vaccines9101148 · Cited by 16
SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia
Brown, L. M., Hediyeh-zadeh, S., Sadras, T., Huckstep, H., Sandow, J. J., Bartolo, R. C., Kosasih, H. J., Davidson, N., Schmidt, B., Bjelosevic, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006076 · Cited by 14
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
Molinaro, E., Andrikou, K., Gardini, A. C., & Rovesti, G. (2020) · Cancers · doi:10.3390/cancers12113346 · Cited by 15
Clinical efficacy of PARP inhibitors in breast cancer
Pandya, K., Scher, A., Omene, C. O., Ganesan, S., Kumar, S., Ohri, N., Potdevin, L. B., Haffty, B. G., Toppmeyer, D., & George, M. A. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06940-0 · Cited by 16
Xiao, L., Zhang, J., Yang, Y., Hong, H., Han, L., & Ning, Z. H. (2021) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2021.122079 · Cited by 15
Inibidores da PARP: do mecanismo de ação à prática clínica
Branco, C., & Paredes, J. (2022) · Acta Médica Portuguesa · doi:10.20344/amp.13870 · Cited by 16
Okamoto, A., Kondo, E., Nakamura, T., Yanagida, S., Hamanishi, J., Harano, K., Hasegawa, K., Hirasawa, T., Hori, K., Komiyama, S., et al. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e16 · Cited by 15
Keller, B. A., Pastukhova, E., Lo, B., Sekhon, H. S., & Flood, T. A. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0592-ra · Cited by 15
Sinha, A., Katyal, S., & Kauppinen, T. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108502 · Cited by 16
Huang, C., Tsai, Y., Liu, C., Lien, P., Lin, Y., Chao, T., Feng, C.-J., Chen, Y.-J., Lai, J., Phan, N. N., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11347-0 · Cited by 14
Histone Modifying Enzymes in Gynaecological Cancers
Ramarao-Milne, P., Kondrashova, O., Barry, S. C., Hooper, J. D., Lee, J. S., & Waddell, N. (2021) · Cancers · doi:10.3390/cancers13040816 · Cited by 15
Takehara, K., Matsumoto, T., Hamanishi, J., Hasegawa, K., Matsuura, M., Miura, K., Nagao, S., Nakai, H., Tanaka, N., Tokunaga, H., et al. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e21 · Cited by 13
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Yang, S., Green, A., Virani, N. A., Robinson, A., Senat, M., Testino, B., Dinulescu, D. M., & Sridhar, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175617 · Cited by 12
Hoffman, S. L. V., Mixdorf, J. C., Kwon, O., Johnson, T. R., Makvandi, M., Lee, H., Aluicio‐Sarduy, E., Barnhart, T. E., Jeffery, J. J., Patankar, M. S., et al. (2023) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2023.108368 · Cited by 13
Araujo‐Abad, S., Fuentes-Baile, M., Rizzuti, B., Bazán, J. F., Villamarin‐Ortiz, A., Saceda, M., Fernández, E., Vidal, M., Abián, O., Velázquez‐Campoy, A., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125632 · Cited by 11
Mu, S., Palmer, D. H., Fitzgerald, R. J., Andreu‐Vieyra, C., Zhang, H., Tang, Z., Su, D., & Sahasranaman, S. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.943 · Cited by 11
Landry, A., Wang, J. Z., Nassiri, F., Patil, V. S., Gao, A. F., & Zadeh, G. M. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207952 · Cited by 11
PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, P., & Bothra, S. J. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.002 · Cited by 10
Designing an anticancer Pd(II) complex as poly(ADP-ribose) polymerase 1 inhibitor
Gai, S., Cao, P., Zhong, X., Lin, Y., Lin, B., & Jiang, M. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139885 · Cited by 9
A Narrative Review on Breast Cancer Treatment Supported by Focused and Systemic Phytotherapy
Machado, H., Machado, J. P., Alves, C. H. F., Monteiro, M. D. C., Cruz, A., Pinho, C., Soares, C. M. D., Grosso, C., Rodrigues, J. M., & Criado, M. B. (2025) · Nutraceuticals · doi:10.3390/nutraceuticals5040037 · Cited by 9
EREG is a risk factor for the prognosis of patients with cervical cancer
Li, T., Feng, R., Chen, B., & Zhou, J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1161835 · Cited by 9
Zhang, Y., Li, Q., Lan, J., Xie, G., Zhang, G., Cui, J., Leng, P., & Wang, Y. (2025) · Carcinogenesis · doi:10.1093/carcin/bgaf006 · Cited by 10
Immune monitoring of neoadjuvant chemo-immunotherapy for triple-negative breast cancer
Syeda, M. F., Santos, R. A., Sousa, L. M., Paiva, A. R., Branco, N. C., Pereira, T. C., Sousa, G., & Rodrigues‐Santos, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1654748 · Cited by 10
WGS Data Collections: How Do Genomic Databases Transform Medicine?
Król, Z. J., Dobosz, P., Ślubowska, A., & Mroczek, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24033031 · Cited by 8
Shin, Y., Kim, M.-K., Kim, C., Jeon, H., Koo, J., Oh, J., Shin, S., Youn, Y. S., Lim, C., & Oh, K. T. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02927-2 · Cited by 8
TP53 Co-Mutational Features and NGS-Calibrated Immunohistochemistry Threshold in Gastric Cancer
Yu, R., Sun, T., Zhang, X., Li, Z., Xu, Y., Liu, K., Shi, Y., Wu, X., Shao, Y. W., & Kong, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s321949 · Cited by 8
RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity
Maybee, D. V., Psaras, A. M., Brooks, T. A., & Ali, M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911764 · Cited by 9
Mu, S., Lin, C., Skrzypczyk-Ostaszewicz, A., Bulat, I., Maglakelidze, M., Skarbová, V., Andreu‐Vieyra, C., & Sahasranaman, S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04253-x · Cited by 8
Bošnjak, M., Jesenko, T., Markelc, B., Janžič, L., Čemažar, M., & Serša, G. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107832 · Cited by 8
Shyrokova, L., Prassolov, V., & Spirin, P. (2021) · Acta Naturae · doi:10.32607/actanaturae.11181 · Cited by 7
Das, A., Mandal, S. K., Arya, S., Samanta, S. K., Kumar, A., Panchpuri, M., Abdel‐Gawad, H., Dwibedi, V., Das, N., Bose, S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108558 · Cited by 7
Computational Chemistry Advances in the Development of PARP1 Inhibitors for Breast Cancer Therapy
Twala, C., Govender, P. P., & Govender, K. K. (2025) · Pharmaceuticals · doi:10.3390/ph18111679 · Cited by 7
A therapeutic update on PARP inhibitors: implications in the treatment of glioma
Lal, S., & Snape, T. J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.029 · Cited by 6
Hussain, M., Khadka, P., Pekhale, K., Kulikowicz, T., Gray, S. H., May, A., Croteau, D. L., & Bohr, V. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01383-z · Cited by 5
Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression
Drakes, M. L., & Stiff, P. J. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73359-9_3 · Cited by 5
Wan, H., Wei, J.-P., Wang, Y., Ge, L., Hu, Q., Li, Y., Zhou, B., & Zeng, X. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111693 · Cited by 4
PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting
Milano, G. A. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04016-9 · Cited by 4
Lin, G.-B., Chen, W., Kuo, Y.-Y., Liu, H.-H., Chen, Y.-M., Leu, S. J., & Chao, C.-Y. (2025) · Oncology Reports · doi:10.3892/or.2025.8891 · Cited by 4
Abualsoud, B. M., Alhomrani, M., Alamri, A. S., Alsanie, W. F., Ballal, S., Sharma, G. C., Krithiga, T., Singh, A., Kumar, A., & Deepak, A. (2025) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2025.2534698 · Cited by 5
Fully Automated, High-Dose Radiosynthesis of [18F]PARPi
Pacelli, A., Zarrad, F., Warnier, C., Gendron, T., Otabashi, M., Vriamont, C., Jackson, A. R., Fendler, W. P., Herrmann, K., & Nader, M. (2022) · Pharmaceuticals · doi:10.3390/ph15070865 · Cited by 4
Zhang, Y., Liang, L., Li, Z., Huang, Y., Jiang, M., Zou, B., & Xu, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1295579 · Cited by 3
Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review
Pasupulati, S. L., Rao, K. S., Sharma, S. K., Madhavrao, C., Rangari, G. M., Misra, A. K., Kutikuppala, L. V. S., Devika, T., & Sarikonda, S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04810-8 · Cited by 3
Zhu, L., Liu, B., Jin, F. J., Cao, W., Xu, G., Zhang, X., Peng, P., Gao, D., Wang, B., & Feng, K. (2024) · Molecules · doi:10.3390/molecules29061407 · Cited by 3
Patient Informed Domain Adaptation Improves Clinical Drug Response PredictionPreprint
Anastopoulos, I. N., Seninge, L., Ding, H., & Stuart, J. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.07.455527 · Cited by 3
Aoki, D., Tabata, T., Yanagida, S., Nakamura, T., Kondo, E., Hamanishi, J., Harano, K., Hasegawa, K., Hirasawa, T., Hori, K., et al. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e114 · Cited by 2
Medulloblastoma and the DNA Damage Response
McSwain, L., Parwani, K. K., Shahab, S., Hambardzumyan, D., MacDonald, T. J., Spangle, J. M., & Kenney, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903830 · Cited by 2
Pérez-Peiró, M., Durán, X., Yélamos, J., & Barreiro, E. (2022) · Cancers · doi:10.3390/cancers14122894 · Cited by 3
Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
Grzelak, D. (2021) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2021.12.5.4 · Cited by 2
Resistance to HER2-Targeted Therapies Results in Upregulation of MCL-1 and Sensitivity to Olaparib
Armstrong, A., Najor, M., Rempert, T. H., Bishehsari, F., Abukhdeir, A. M., & Cobleigh, M. (2020) · International Journal of Sciences · doi:10.18483/ijsci.2407 · Cited by 2
Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts
Raimo, T. D., & Angelini, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082377 · Cited by 1
Multiomics Approach to Understanding Olaparib Resistance and Predicting Drug ResponsePreprint
Lim, W.-J., Kim, H. M., Oh, Y., & Pyo, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.04.535542 · Cited by 1
Wei, Y., Wei, C., Liang, C., Liu, N., Fang, Z., Yin, J. C., Pang, J., Ou, Q., Wu, X., Wang, X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-84299/v1
Huang, C., Liu, C., Tsai, Y., Lien, P., Lin, Y., Chao, T., Feng, C.-J., Chen, Y.-J., Lai, J., Phan, N. N., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-366269/v1
Metadata
- Authors
- Yi, M., Dong, B., Qin, S., Chu, Q., Wu, K., & Luo, S.
- Affiliations
- Tongji Hospital (CN)
- Zhengzhou University (CN)
- Corresponding author
- Wu, Kongming
- Luo, Suxia
- Venue
- Experimental Hematology & Oncology
- Published
- 2019-11-11
- Volume
- 8
- Issue
- 1
- Pages
- 29-29
- ISSN
- 2162-3619 (ISSN-L)
- PMC
- PMC6849303
- OpenAlex
- W2987653633
- Cited by
- 117
- References
- 104
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 7 · 2023: 18 · 2022: 19 · 2021: 33 · 2020: 22
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Experimental Hematology and Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (81874120, 81572608, 81672984)
- Wuhan Municipal Science and Technology Bureau (2017060201010170)
- Natural Science Foundation of Henan Province (162300410266)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- PARP inhibitors, DNA repair deficiency, synthetic lethality, BRCA mutations, homologous recombination deficiency, single-strand break repair, genomic instability, PARP inhibitor resistance, combination therapy, immune checkpoint inhibitors, combination chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
